Allogeneic bone marrow transplatation in a patient with Shwachman-Diamond syndrome.
Shwachman-Diamond syndrome (SDS) is a rare inherited disorder involving concomitant neutropenia and exocrine pancreatic insufficiency. About 25% of patients develop hematopoietic malignancies. We describe a 24-year-old male patient with SDS who underwent allogeneic bone marrow transplantation (BMT) because of progression into acute myeloid leukemia (AML) following myelodysplastic syndrome (MDS). The BMT preparative regimen consisted of busulfan (16 mg/kg body wt.), followed by cyclophosphamide (120 mg/kg). Cyclosporin A and short methotrexate were used for graft-versus-host disease (GvHD) prophylaxis. The post-transplant period was complicated by staphylococcal septicemia, CMV infection, renal insufficiency, and acute GvHD grade III. Hematological recovery was delayed (post-transplant day +55). The patient was discharged at day +68 in complete remission without any evidence of MDS. RFLP fingerprint analysis showed complete engraftment of the donor's hematopoiesis. The patient's leukemia relapsed 9 months post-transplant, and death followed due to CMV infection and multiorgan failure. Despite the fatal course in this patient, allogeneic BMT could be an option for curative treatment of the hematopoietic failure in SDS. The interaction of BMT with pancreatic insufficiency still has to be ascertained.
Arseniev
L
L
Department of Hematology and Oncology, Medizinische Hochschule Hannover, Germany.
Diedrich
H
H
Link
H
H
D000328:Adult; D016026:Bone Marrow Transplantation; D016572:Cyclosporine / Q000627:therapeutic use; D010188:Exocrine Pancreatic Insufficiency / Q000473:pathology / Q000628:therapy*; D017809:Fatal Outcome; D005260:Female; D006086:Graft vs Host Disease / Q000188:drug therapy; D006801:Humans; D015479:Leukemia, Myelomonocytic, Acute / Q000473:pathology*; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D011247:Pregnancy; D013577:Syndrome
D016572:Cyclosporine; D008727:Methotrexate